Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Active, not recruiting · NCT04879628 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 2 | 2026-09-28 | NCT04879628 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sanofi | 254 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Center for Neurology and Spine- Site Number : 8400007 | Phoenix | United States | 1 |
| Medical College of Wisconsin- Site Number : 8400006 | Milwaukee | United States | 1 |
| The Neurological Institute Site Number : 8400004 | Charlotte | United States | 1 |
| University of South Florida Site Number : 8400001 | Tampa | United States | 1 |